08:51 AM EDT, 04/21/2026 (MT Newswires) -- Foundation Medicine said Tuesday that it has expanded its collaboration with Bristol Myers Squibb ( BMY ) to develop a next-generation sequencing companion diagnostic for identifying patients with homozygous MTAP deletion across multiple cancer types.

The companies said they will enhance the use of FoundationOne CDx, an FDA-approved genomic test, to more precisely detect copy number loss linked to MTAP deficiency, a biomarker associated with response to targeted cancer therapies.

Foundation Medicine said the expansion builds on its long-standing partnership with Bristol Myers Squibb ( BMY ) to advance biomarker-driven drug development and precision oncology approaches.

Financial details of the expanded collaboration were not disclosed.